These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11072160)

  • 1. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.
    Wasserman T; Mackowiak JI; Brizel DM; Oster W; Zhang J; Peeples PJ; Sauer R
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1035-9. PubMed ID: 11072160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
    Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
    Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of amifostine on dental health after radiotherapy of the head and neck.
    Rudat V; Meyer J; Momm F; Bendel M; Henke M; Strnad V; Grötz K; Schulte A
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1339-43. PubMed ID: 11121631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
    Batcha M
    Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
    [No Abstract]   [Full Text] [Related]  

  • 13. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
    Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
    Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
    Anné PR; Machtay M; Rosenthal DI; Brizel DM; Morrison WH; Irwin DH; Chougule PB; Estopinal NC; Berson A; Curran WJ
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):445-52. PubMed ID: 17141978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
    Nicolatou-Galitis O; Sotiropoulou-Lontou A; Velegraki A; Pissakas G; Kolitsi G; Kyprianou K; Kouloulias V; Papanikolaou I; Yiotakis I; Dardoufas K
    Oral Oncol; 2003 Jun; 39(4):397-401. PubMed ID: 12676261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
    Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
    Büntzel J; Küttner K; Fröhlich D; Glatzel M
    Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.